1 Division of Oncology, The Children's Hospital of Philadelphia , Philadelphia, Pennsylvania.
2 Asuragen, Inc. , Austin, Texas.
Thyroid. 2018 Jan;28(1):60-67. doi: 10.1089/thy.2017.0059. Epub 2017 Dec 11.
Thyroid nodules are less common in pediatric patients (i.e., those ≤18 years) than they are in adults. The Bethesda System for Reporting Thyroid Cytopathology allows for individual risk stratification, but a significant number of nodules are indeterminate. Incorporating gene mutation panels and gene expression classifiers may aid in preoperative diagnosis. The overall aim of this study was to assess the prevalence of oncogene alterations in a representative pediatric population and across a broad-spectrum of thyroid tumor diagnoses.
This was a retrospective cross-sectional evaluation of 115 archived samples, including: 47 benign (29 follicular adenoma, 11 diffuse hyperplasia, four thyroiditis, and three multinodular goiter), six follicular thyroid carcinomas (FTC), 24 follicular variant of papillary thyroid carcinomas (fvPTC), 27 classic variant of PTC (cPTC), eight diffuse sclerosing variant of PTC (dsvPTC), and three other PTC. Molecular testing was performed by multiplex qualitative polymerase chain reaction followed by bead array cytometry. Oncogene results were analyzed for association with age, sex, histology, lymph node metastasis, and intrathyroidal spread.
A mutation in one of the 17 molecular markers evaluated was found in: 2/6 (33%) FTC, 8/24 (33%) fvPTC, 17/27 (63%) cPTC, and 4/8 (50%) dsvPTC. Mutations in RAS or PAX8/PPARG were exclusive to FTC and fvPTC. BRAF was the most common mutation in cPTC (12/17; 71%), and RET/PTC was the only mutation associated with dsvPTC. Overall, a mutation was found in 32/68 (47%) malignant specimens, with a single follicular adenoma positive for PAX8/PPARG. The relative distribution of gene alterations in pediatric lesions was similar to adults. The presence of a BRAF mutation in pediatric cPTC did not predict a more invasive phenotype.
Of 33 nodules with genetic alterations, 32 were malignant. Mutations in RAS were most frequently associated with FTC, RET/PTC rearrangements with dsvPTC, and invasive fvPTC, and BRAF with cPTC. These results suggest a clinical role for mutational analysis of pediatric nodules to guide the surgical approach.
甲状腺结节在儿科患者(即≤18 岁的患者)中比在成人中少见。甲状腺细胞病理学报告的 Bethesda 系统允许进行个体风险分层,但相当数量的结节是不确定的。纳入基因突变面板和基因表达分类器可能有助于术前诊断。本研究的总体目的是评估代表性儿科人群中癌基因改变的患病率,并评估广泛的甲状腺肿瘤诊断。
这是对 115 个存档样本的回顾性横断面评估,包括:47 个良性(29 个滤泡性腺瘤、11 个弥漫性增生、4 个甲状腺炎和 3 个多结节性甲状腺肿)、6 个滤泡状甲状腺癌(FTC)、24 个滤泡状甲状腺癌变体。乳头状甲状腺癌(fvPTC)、27 个经典型甲状腺癌(cPTC)、8 个弥漫性硬化型甲状腺癌(dsvPTC)和 3 个其他甲状腺癌。通过多重定性聚合酶链反应 followed 珠阵列细胞术进行分子检测。对癌基因结果进行分析,以确定与年龄、性别、组织学、淋巴结转移和甲状腺内播散的关系。
在评估的 17 个分子标记物中,有一个发生了突变:2/6(33%)FTC、8/24(33%)fvPTC、17/27(63%)cPTC 和 4/8(50%)dsvPTC。RAS 或 PAX8/PPARG 中的突变仅见于 FTC 和 fvPTC。BRAF 是 cPTC 中最常见的突变(12/17;71%),而 RET/PTC 是唯一与 dsvPTC 相关的突变。总体而言,32/68(47%)恶性标本存在突变,单个滤泡性腺瘤存在 PAX8/PPARG 阳性。儿科病变中基因改变的相对分布与成人相似。儿科 cPTC 中 BRAF 突变的存在并不预示着侵袭性表型。
在 33 个具有遗传改变的结节中,有 32 个是恶性的。RAS 中的突变最常与 FTC 相关,RET/PTC 重排与 dsvPTC 相关,侵袭性 fvPTC 与 BRAF 相关,而 cPTC 与 BRAF 相关。这些结果表明,对儿科结节进行基因突变分析以指导手术方法具有临床意义。